Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
https://doi.org/10.14341/2072-0351-6226
Abstract
The review is devoted to the pharmacological effects, the results of clinical trials, safety and the research perspectives of the first incretinomimetic exenatide
About the Authors
Alexander Sergeevich Ametov
Russian Medical Academy of Postgraduate Training, Moscow
Lyudmila Leonidovna Kamynina
Russian Medical Academy of Postgraduate Training, Moscow
References
1. Cvetković R.S., Plosker G.L. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea) // Drugs. - 2007. - № 67(6). - P. 935-954.
2. Mafong D.D., Henry R.R. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction // Curr Atheroscler Rep. - 2008. - № 10 (1). - P. 55-60.
3. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., Brodows R., Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study // Diabetologia. - 2007. - № 50 (2). - P. 259-267.
4. DeFronzo R.A, Triplitt C., Qu Y., Lewis M.S., Maggs D., Glass L.C. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin // Diabetes Care. - 2010. - № 33 (5). - Р. 951-957.
5. Norris S.L., Lee N., Thakurta S., Chan B.K. Exenatide efficacy and safety: a systematic review // Diabet Med. - 2009. - № 26 (9). - Р. 837-846.
6. Аметов А.С., Пьяных О.П., Ильичева А.В. Последние достижения в лечении сахарного диабета типа 2: эксенатид - первый экзо- генный инкретиномиметик инкретина глюкагоно-подобного пеп- тида-1 // Фарматека. - 2008. - № 2. - С. 10-15.
7. Викулова О.К., Шестакова М.В. Клиническая эффективность миме- тика инкретинов эксенатида: результаты исследований и показания к применению у больных сахарным диабетом типа 2 // Consilium Medicum. - 2008. - № 10 (9). - С. 35-41.
8. Moretto T.J., Milton D.R., Ridge T.D., Macconell L.A., Okerson T., Wolka A.M., Brodows R.G. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study // Clin Ther. - 2008. - № 30 (8). - Р. 1448-1460.
9. Apovian C.M., Bergenstal R.M., Cuddihy R.M., Qu Y., Lenox S., Lewis M.S., Glass L.C. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes // Am. J. Med. - 2010. - № 123 (5). - Р. 468. e9-17.
10. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes // Diabetes Care. - 2005. - № 28 (5). - Р. 1092-1100.
11. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea // Diabetes Care. - 2005. - № 28 (5). - Р. 1083-1091.
12. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D.; Exenatide- 113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes // Diabetes Care. - 2004. - № 27 (11). - Р. 2628-2635.
13. Pinelli N.R., Cha R., Brown M.B., Jaber L.A. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis // Ann Pharmacother. - 2008. - № 42 (11). - Р. 1541-1551.
14. Davies M.J., Donnelly R., Barnett A.H., Jones S., Nicolay C., Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study // Diabetes Obes Metab. - 2009. - № 11 (12). - Р. 1153-1162.
15. Garg S.K. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes - a comprehensive review // Diabetes Technol Ther. - 2010. - № 12 (1). - Р. 11-24.
16. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G.; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial // Ann. Intern. Med. - 2005. - № 143 (8). - Р. 559-569.
17. Riddle M.C., Henry R.R., Poon T.H., Zhang B., Mac S.M., Holcombe J.H., Kim D.D., Maggs D.G. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin // Diabetes Metab. Res. Rev. - 2006. - № 22 (6). - Р. 483-491.
18. Mittendorf T., Smith-Palmer J., Timlin L. et al. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting // Diabetes Obes. Metab. - 2009. - № 11 (11). - Р. 1068-1079.
19. Gallwitz B. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus // Drug Saf. - 2010. - № 33 (2). - Р. 87-100.
20. Анциферов М.Б., Котешкова О.М., Ситников В.В., Митяева О.А., Пашинцева Л.П., Буданцева Т.А., Иванова Е.А. Опыт применения инкритиномиметика эксенатид (Баета) в лечении больных сахарным диабетом типа 2 с ожирением // Фарматека. - 2009. - № 3. - C. 32-37.
21. Gill A., Hoogwerf B.J., Burger J., Bruce S., Macconell L., Yan P., Braun D., Giaconia J., Malone J. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study // Cardiovasc Diabetol. - 2010. - № 9. - Р. 6.
22. Brixner D.I., McAdam-Marx C., Ye X., Boye K.S., Nielsen L.L., Wintle M., Misurski D., Fabunmi R. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting // Diabetes Obes. Metab. - 2009. - № 11 (12). - Р. 1122-1130.
23. Аметов А.С. Влияние терапии эксенатидом на различные показатели метаболизма и факторы риска диабетических осложнений у боль- ных сахарным диабетом 2 типа // РМЖ. - 2008. - № 16 (28). - C. 1862-1869.
24. Bunck M.C., Diamant M., Eliasson B., Cornér A., Shaginian R.M., Heine R.J., Taskinen M.R., Yki-Järvinen H., Smith U. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition // Diabetes Care. - 2010. - № 33 (8). - Р. 1734-1737.
25. Anagnostis P., Athyros V.G., Adamidou F., Panagiotou A., Kita M., Karagiannis A., Mikhailidis D.P. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control // Diabetes Obes. Metab. - 2011. - № 13 (4). - Р. 302-132.
26. Ratner R., Han J., Nicewarner D., Yushmanova I., Hoogwerf B.J., Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes // Cardiovasc Diabetol. - 2011. - № 10. - Р. 22.
27. Bunck M.C., Eliasson B., Cornér A., Heine R.J., Shaginian R.M., Taskinen M.R., Yki-Järvinen H., Smith U., Diamant M. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes // Diabetes Obes. Metab. - 2011. - № 13 (4). - Р. 374-377.
28. Hiles R.A., Bawdon R.E., Petrella E.M. Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4) // Hum. Exp. Toxicol. - 2003. - № 22 (12). - Р. 623-628.
Review
For citations:
Ametov A.S., Kamynina L.L. Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide. Diabetes mellitus. 2011;14(3):63-68. (In Russ.) https://doi.org/10.14341/2072-0351-6226
Views:
1306
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
